Project Grant HT94252310831
Award Date
9/15/23
Completion Date
9/14/25
Dollars Obligated
$334K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The federal Project Grant award with ID HT94252410711, titled "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,568,220.00 grant, with a performance period from Sep 15, 2024 to Sep 14, 2027, was awarded to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). Through this funding, MGH will conduct...
The federal Project Grant award, valued at $888,632.00 and awarded on April 1, 2025, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the role of maternal autoantibodies in inducing behavioral abnormalities in offspring following maternal TLR7 activation. This advanced biomedical research...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
The U.S. Defense Health Agency awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $1,140,766 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The award, effective September 1, 2024 through August 31, 2027, will fund a novel mHealth balance assessment and rehabilitation project using computer vision and AI for patients with neurofibromatosis type 2 (NF2). MGH, as the primary research institution, will...
The General Hospital Corporation, doing business as Massachusetts General Hospital, received a $587,117 project grant from the Defense Health Agency's Military Medical Research and Development program to develop an online platform promoting evidence-based care for patients with neurofibromatosis 1. The three-year grant, awarded June 1, 2023 and set to be completed by May 31, 2026, aims to address medical and social barriers to care through tailoring an online resource to provide specialized...
The Department of the Army Medical Command awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $992,302.00 project grant under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. Specifically, the award funds research to target MHC II ubiquitination in order to induce immune...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $1,865,846 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on July 1, 2024. The funding will support the project "TARGETING NEUROIMMUNE AND EPITHELIAL SIGNALING FOR ECZEMA TREATMENT" through June 30, 2028. MGH, a leading academic medical center and research institution, will conduct biomedical research,...
The Defense Health Agency awarded a $1,621,712 Project Grant to The General Hospital Corporation's Research Management Division, operating as Massachusetts General Hospital (MGH), for the "THERAPEUTIC TARGETING OF CHEMORESISTANT RHABDOMYOSARCOMA" project. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research initiatives to improve health outcomes for military service members, veterans, and the...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,328,936 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 3-year research project titled "Elucidating Tumor Intrinsic and Extrinsic Drivers of Mucosal Melanoma". The grant, awarded on Sep 30, 2023, will fund MGH's biomedical research efforts to study the genetic and epigenetic landscape of mucosal melanoma,...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,424,067 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the "DEVELOPMENT OF ANTI-DYT1 DYSTONIA GENE EDITING THERAPIES". The grant, with a performance period from Jul 1, 2024 to Jun 30, 2028, will support MGH's research to develop new gene editing therapies for treating DYT1 dystonia, a rare neurological disorder. As...